Aarthi Muthukumaran retweetledi

Most kidney trials whisper.
This one doesn’t.
@NEJM Phase 3 interim analysis in NEJM:
telitacicept cut proteinuria by 58.9% vs 8.8% placebo in high-risk IgA nephropathy.
eGFR at 39 weeks: -1.0% vs -7.7%.
Dual BAFF/APRIL blockade may be hitting disease upstream.
#IgAN #Nephrology #KidneyDisease #Glomerulonephritis

English







































